Trial Profile

A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HER2-CAR transduced T-cells (Primary) ; TT-16 (Primary) ; Pembrolizumab
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Lung cancer; Oesophageal cancer; Pancreatic cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms VISTA

Most Recent Events

07 Feb 2025 Planned primary completion date changed from 30 Dec 2024 to 30 Dec 2025.
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
23 Jun 2021 Status changed from planning to recruiting, according to a Tessa Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com